Rotigotine Transdermal Patches Market, By Type (1mg, 2mg, 3mg, 4mg, 6mg, and 8mg), By Application (Treatment of Parkinson's, and Others), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis and Forecast till 2032

Report Code: PMI264619 | Publish Date: December 2023 | No. of Pages: 182

Global Rotigotine Transdermal Patches Market Overview

Rotigotine Transdermal Patches are dopamine agonist which works on nervous system and used for treating Parkinson’s disease. It is also used for treating conditions such as Restless Legs Syndrome (RLS).  

Global Rotigotine Transdermal Patches Market Drivers & Restraints

Drivers

Restrains

Rising prevalence of Parkinson’s disease across globe

Complications and side-effects such as lightheaded, drowsy and dizziness

Less invasive

High costs

Provides faster results

 
Access Crucial Insights at a Fraction of the Cost | Request Your Discount

Global Rotigotine Transdermal Patches Market Segmentations & Regional Insights

The target market is segmented based on Type, Application, and Region.

Type Insight

On the basis of Type, the target market is segmented into 1mg, 2mg, 3mg, 4mg, 6mg, and 8mg.

Application Insight

On the basis of Application, the target market is segmented into Treatment of Parkinson's, and Others.

Regional Insights:

On region the target market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

North America market is estimated to witness a significantly high revenue share over the forecast period.

  • High prevalence of Parkinson’s disease.
  • Robust healthcare infrastructure.

Asia Pacific market is estimated to witness a fastest revenue share over the forecast period.

  • Rising burden of Parkinson’s disease in emerging economies such as China in the world.
  • Rising awareness among patients regarding Parkinson’s diseases.
  • Improved healthcare infrastructure.
Reduce costs by up to 30% with a custom report tailored to your specific needs | Request Customized Report

The key players operating the target market includes, UCB (Union Chimique Belge).

Global Rotigotine Transdermal Patches Market Company Profile

Recent Development:

             The New Launched Product News,

  • In July 2007, UCB and its subsidiary SCHWARZ PHARMA launched the new “Neupro” (Rotigotine Transdermal System) for treating early-stage of Parkinson’s disease. The Neupro has become the first and only Parkinson’s patch which can be wear on skin and delivers the dopamine agonist rotigotine through skin into bloodstream and thus, releases the medicine for 24 hours throughout day and night.

Report Scope:

Attribute

Details

Base year for estimation

2022

Forecast period

2022 – 2032

Market representation

Revenue in USD Billion & CAGR from 2022 to 2032

Market Segmentation

By Type - 1mg, 2mg, 3mg, 4mg, 6mg, and 8mg

By Application - Treatment of Parkinson's, and Others

Regional scope

North America - U.S., Canada

Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe

Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific

Latin America - Brazil, Mexico, Argentina, Rest of Latin America

Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa

Report coverage

Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2022 to 2032.

Few Other Promising Reports:

FAQs

By region, the target market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The North America market is estimated to witness a significantly high revenue share over the forecast period.

The key players operating the target market includes, UCB ((Union Chimique Belge).